Ensysce Biosciences (ENSC, Financial) has recently filed to offer 652,439 shares of its common stock. This move, while still preliminary, could signal important shifts in the company's stock dynamics and financial strategies, making it a key point of interest for investors.
- Ensysce Biosciences (ENSC, Financial) plans to offer over 650,000 shares.
- Analysts project significant upside potential with a target price of $46.73.
- Current recommendation status is "Outperform" based on analyst consensus.
Wall Street Analysts Forecast
According to projections by two market analysts, Ensysce Biosciences Inc (ENSC, Financial) has a promising outlook. The average price target is set at $46.73, with estimates ranging from a high of $75.00 to a low of $18.45. This suggests a compelling potential upside of 2,385.37% from its current trading price of $1.88. For a comprehensive view of these projections, visit the Ensysce Biosciences Inc (ENSC) Forecast page.
The consensus among brokerage firms gives Ensysce Biosciences Inc an average recommendation score of 2.0, placing it in the "Outperform" category. This recommendation is based on a scale where 1 represents a Strong Buy and 5 indicates a Sell, reflecting analysts' confidence in the stock's potential.
